UOC
PMVP icon

UBS O'Connor’s PMV Pharmaceuticals PMVP Stock Holding History

UBS O'Connor’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-56,852
Closed -$96.6K – 620
2024
Q1 		$96.6K Sell
56,852
-69,148
-55% -$129K ﹤0.01% 426
2023
Q4 		$391K Buy
+126,000
New +$333K 0.01% 374

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

UBS O'Connor's PMVP Position: Q2 2024 in Review

UBS O'Connor sold out of PMV Pharmaceuticals (PMVP) in Q2 2024, closing a stake of 56,852 shares — an estimated $96.6K sold.

UBS O'Connor first reported a position in PMVP in Q4 2023 and held it in 2 quarters. The position peaked at $391K in Q4 2023. 93 funds tracked by Wall St. Rank hold PMVP as of Q2 2024.

  • UBS O'Connor reported no remaining PMV Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • UBS O'Connor sold 56,852 PMV Pharmaceuticals shares in Q2 2024, an estimated $96.6K.
  • UBS O'Connor first reported a position in PMV Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • UBS O'Connor's PMV Pharmaceuticals position peaked at $391K in Q4 2023.
  • 93 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2024.

Based on UBS O'Connor's 13F filing for Q2 2024, filed 14 Aug 2024.